Selected research
Market Structure
Global CAR T-Cell Therapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global CAR T-Cell Therapy market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for CAR T-Cell Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for CAR T-Cell Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for CAR T-Cell Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for CAR T-Cell Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of CAR T-Cell Therapy include J & J, Novartis, Sorrento Therapeutics(Pipeline), Mustang Bio(Pipeline), JW Therapeutics, Gilead Sciences, FOSUNKite, Celyad(Pipeline) and Cellectis(Pipeline), among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global CAR T-Cell Therapy market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of CAR T-Cell Therapy and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents CAR T-Cell Therapy revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the CAR T-Cell Therapy market size, projected growth trends, production technologies, key applications, and end-use industries.
CAR T-Cell Therapy Segment by Company
J & J
Novartis
Sorrento Therapeutics(Pipeline)
Mustang Bio(Pipeline)
JW Therapeutics
Gilead Sciences
FOSUNKite
Celyad(Pipeline)
Cellectis(Pipeline)
CARsgen Therapeutics (Pipeline)
Bristol-Myers Squibb
Bluebird Bio(Pipeline)
Autolus Therapeutics(Pipeline)
Allogene Therapeutics(Pipeline)
CAR T-Cell Therapy Segment by Type
CD19 - Targeted
BCMA - Targeted
CAR T-Cell Therapy Segment by Application
Lymphoma
Multiple Myeloma
CAR T-Cell Therapy Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CAR T-Cell Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of CAR T-Cell Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CAR T-Cell Therapy.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of CAR T-Cell Therapy in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global CAR T-Cell Therapy industry.
Chapter 3: Detailed analysis of CAR T-Cell Therapy companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, CAR T-Cell Therapyrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- CD19 - Targeted
- BCMA - Targeted
Applications
- Lymphoma
- Multiple Myeloma
Companies covered
- J & J
- Novartis
- Sorrento Therapeutics(Pipeline)
- Mustang Bio(Pipeline)
- JW Therapeutics
- Gilead Sciences
- FOSUNKite
- Celyad(Pipeline)
- Cellectis(Pipeline)
- CARsgen Therapeutics (Pipeline)
- Bristol-Myers Squibb
- Bluebird Bio(Pipeline)
- Autolus Therapeutics(Pipeline)
- Allogene Therapeutics(Pipeline)
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global CAR T-Cell Therapy Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 CD19 - Targeted
- 1.2.3 BCMA - Targeted
- 1.3 Market Analysis by Application
- 1.3.1 Global CAR T-Cell Therapy Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Lymphoma
- 1.3.3 Multiple Myeloma
- 1.4 Global Market Growth Prospects
- 1.5 Global CAR T-Cell Therapy Growth Trends by Region
- 1.5.1 Global CAR T-Cell Therapy Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 CAR T-Cell Therapy Market Size by Region (2021-2026)
- 1.5.3 CAR T-Cell Therapy Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global CAR T-Cell Therapy Market Dynamics
- 2.1 CAR T-Cell Therapy Industry Trends
- 2.2 CAR T-Cell Therapy Industry Drivers
- 2.3 CAR T-Cell Therapy Industry Opportunities and Challenges
- 2.4 CAR T-Cell Therapy Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global CAR T-Cell Therapy Revenue by Company (2021-2026)
- 3.2 Global CAR T-Cell Therapy Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global CAR T-Cell Therapy Key Company Head office and Area Served
- 3.4 Global CAR T-Cell Therapy Company, Product Type & Application
- 3.5 Global CAR T-Cell Therapy Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global CAR T-Cell Therapy Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 CAR T-Cell Therapy Players Market Share by Revenue in 2025
- 3.6.3 2025 CAR T-Cell Therapy Tier 1, Tier 2, and Tier 3
4 CAR T-Cell Therapy Market by Type
- 4.1 Global CAR T-Cell Therapy Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global CAR T-Cell Therapy Market Size by Type (2021-2032)
- 4.3 Global CAR T-Cell Therapy Market Size Share by Type (2021-2032)
5 CAR T-Cell Therapy Market by Application
- 5.1 Global CAR T-Cell Therapy Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global CAR T-Cell Therapy Market Size by Application (2021-2032)
- 5.3 Global CAR T-Cell Therapy Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 J & J
- 6.1.1 J & J Company Information
- 6.1.2 J & J Business Overview
- 6.1.3 J & J CAR T-Cell Therapy Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 J & J CAR T-Cell Therapy Product Portfolio
- 6.1.5 J & J Recent Developments
- 6.2 Novartis
- 6.2.1 Novartis Company Information
- 6.2.2 Novartis Business Overview
- 6.2.3 Novartis CAR T-Cell Therapy Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 Novartis CAR T-Cell Therapy Product Portfolio
- 6.2.5 Novartis Recent Developments
- 6.3 Sorrento Therapeutics(Pipeline)
- 6.3.1 Sorrento Therapeutics(Pipeline) Company Information
- 6.3.2 Sorrento Therapeutics(Pipeline) Business Overview
- 6.3.3 Sorrento Therapeutics(Pipeline) CAR T-Cell Therapy Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Sorrento Therapeutics(Pipeline) CAR T-Cell Therapy Product Portfolio
- 6.3.5 Sorrento Therapeutics(Pipeline) Recent Developments
- 6.4 Mustang Bio(Pipeline)
- 6.4.1 Mustang Bio(Pipeline) Company Information
- 6.4.2 Mustang Bio(Pipeline) Business Overview
- 6.4.3 Mustang Bio(Pipeline) CAR T-Cell Therapy Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 Mustang Bio(Pipeline) CAR T-Cell Therapy Product Portfolio
- 6.4.5 Mustang Bio(Pipeline) Recent Developments
- 6.5 JW Therapeutics
- 6.5.1 JW Therapeutics Company Information
- 6.5.2 JW Therapeutics Business Overview
- 6.5.3 JW Therapeutics CAR T-Cell Therapy Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 JW Therapeutics CAR T-Cell Therapy Product Portfolio
- 6.5.5 JW Therapeutics Recent Developments
- 6.6 Gilead Sciences
- 6.6.1 Gilead Sciences Company Information
- 6.6.2 Gilead Sciences Business Overview
- 6.6.3 Gilead Sciences CAR T-Cell Therapy Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 Gilead Sciences CAR T-Cell Therapy Product Portfolio
- 6.6.5 Gilead Sciences Recent Developments
- 6.7 FOSUNKite
- 6.7.1 FOSUNKite Company Information
- 6.7.2 FOSUNKite Business Overview
- 6.7.3 FOSUNKite CAR T-Cell Therapy Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 FOSUNKite CAR T-Cell Therapy Product Portfolio
- 6.7.5 FOSUNKite Recent Developments
- 6.8 Celyad(Pipeline)
- 6.8.1 Celyad(Pipeline) Company Information
- 6.8.2 Celyad(Pipeline) Business Overview
- 6.8.3 Celyad(Pipeline) CAR T-Cell Therapy Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 Celyad(Pipeline) CAR T-Cell Therapy Product Portfolio
- 6.8.5 Celyad(Pipeline) Recent Developments
- 6.9 Cellectis(Pipeline)
- 6.9.1 Cellectis(Pipeline) Company Information
- 6.9.2 Cellectis(Pipeline) Business Overview
- 6.9.3 Cellectis(Pipeline) CAR T-Cell Therapy Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 Cellectis(Pipeline) CAR T-Cell Therapy Product Portfolio
- 6.9.5 Cellectis(Pipeline) Recent Developments
- 6.10 CARsgen Therapeutics (Pipeline)
- 6.10.1 CARsgen Therapeutics (Pipeline) Company Information
- 6.10.2 CARsgen Therapeutics (Pipeline) Business Overview
- 6.10.3 CARsgen Therapeutics (Pipeline) CAR T-Cell Therapy Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.10.4 CARsgen Therapeutics (Pipeline) CAR T-Cell Therapy Product Portfolio
- 6.10.5 CARsgen Therapeutics (Pipeline) Recent Developments
- 6.11 Bristol-Myers Squibb
- 6.11.1 Bristol-Myers Squibb Company Information
- 6.11.2 Bristol-Myers Squibb Business Overview
- 6.11.3 Bristol-Myers Squibb CAR T-Cell Therapy Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.11.4 Bristol-Myers Squibb CAR T-Cell Therapy Product Portfolio
- 6.11.5 Bristol-Myers Squibb Recent Developments
- 6.12 Bluebird Bio(Pipeline)
- 6.12.1 Bluebird Bio(Pipeline) Company Information
- 6.12.2 Bluebird Bio(Pipeline) Business Overview
- 6.12.3 Bluebird Bio(Pipeline) CAR T-Cell Therapy Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.12.4 Bluebird Bio(Pipeline) CAR T-Cell Therapy Product Portfolio
- 6.12.5 Bluebird Bio(Pipeline) Recent Developments
- 6.13 Autolus Therapeutics(Pipeline)
- 6.13.1 Autolus Therapeutics(Pipeline) Company Information
- 6.13.2 Autolus Therapeutics(Pipeline) Business Overview
- 6.13.3 Autolus Therapeutics(Pipeline) CAR T-Cell Therapy Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.13.4 Autolus Therapeutics(Pipeline) CAR T-Cell Therapy Product Portfolio
- 6.13.5 Autolus Therapeutics(Pipeline) Recent Developments
- 6.14 Allogene Therapeutics(Pipeline)
- 6.14.1 Allogene Therapeutics(Pipeline) Company Information
- 6.14.2 Allogene Therapeutics(Pipeline) Business Overview
- 6.14.3 Allogene Therapeutics(Pipeline) CAR T-Cell Therapy Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.14.4 Allogene Therapeutics(Pipeline) CAR T-Cell Therapy Product Portfolio
- 6.14.5 Allogene Therapeutics(Pipeline) Recent Developments
7 North America
- 7.1 North America CAR T-Cell Therapy Market Size (2021-2032)
- 7.2 North America CAR T-Cell Therapy Market Size by Type
- 7.2.1 North America CAR T-Cell Therapy Market Size by Type (2021-2026)
- 7.2.2 North America CAR T-Cell Therapy Market Size by Type (2027-2032)
- 7.2.3 North America CAR T-Cell Therapy Market Share by Type (2021-2032)
- 7.3 North America CAR T-Cell Therapy Market Size by Application
- 7.3.1 North America CAR T-Cell Therapy Market Size by Application (2021-2026)
- 7.3.2 North America CAR T-Cell Therapy Market Size by Application (2027-2032)
- 7.3.3 North America CAR T-Cell Therapy Market Share by Application (2021-2032)
- 7.4 North America CAR T-Cell Therapy Market Size by Country
- 7.4.1 North America CAR T-Cell Therapy Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America CAR T-Cell Therapy Market Size by Country (2021-2026)
- 7.4.3 North America CAR T-Cell Therapy Market Size by Country (2027-2032)
- 7.4.4 North America CAR T-Cell Therapy Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe CAR T-Cell Therapy Market Size (2021-2032)
- 8.2 Europe CAR T-Cell Therapy Market Size by Type
- 8.2.1 Europe CAR T-Cell Therapy Market Size by Type (2021-2026)
- 8.2.2 Europe CAR T-Cell Therapy Market Size by Type (2027-2032)
- 8.2.3 Europe CAR T-Cell Therapy Market Share by Type (2021-2032)
- 8.3 Europe CAR T-Cell Therapy Market Size by Application
- 8.3.1 Europe CAR T-Cell Therapy Market Size by Application (2021-2026)
- 8.3.2 Europe CAR T-Cell Therapy Market Size by Application (2027-2032)
- 8.3.3 Europe CAR T-Cell Therapy Market Share by Application (2021-2032)
- 8.4 Europe CAR T-Cell Therapy Market Size by Country
- 8.4.1 Europe CAR T-Cell Therapy Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe CAR T-Cell Therapy Market Size by Country (2021-2026)
- 8.4.3 Europe CAR T-Cell Therapy Market Size by Country (2027-2032)
- 8.4.4 Europe CAR T-Cell Therapy Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China CAR T-Cell Therapy Market Size (2021-2032)
- 9.2 China CAR T-Cell Therapy Market Size by Type
- 9.2.1 China CAR T-Cell Therapy Market Size by Type (2021-2026)
- 9.2.2 China CAR T-Cell Therapy Market Size by Type (2027-2032)
- 9.2.3 China CAR T-Cell Therapy Market Share by Type (2021-2032)
- 9.3 China CAR T-Cell Therapy Market Size by Application
- 9.3.1 China CAR T-Cell Therapy Market Size by Application (2021-2026)
- 9.3.2 China CAR T-Cell Therapy Market Size by Application (2027-2032)
- 9.3.3 China CAR T-Cell Therapy Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia CAR T-Cell Therapy Market Size (2021-2032)
- 10.2 Asia CAR T-Cell Therapy Market Size by Type
- 10.2.1 Asia CAR T-Cell Therapy Market Size by Type (2021-2026)
- 10.2.2 Asia CAR T-Cell Therapy Market Size by Type (2027-2032)
- 10.2.3 Asia CAR T-Cell Therapy Market Share by Type (2021-2032)
- 10.3 Asia CAR T-Cell Therapy Market Size by Application
- 10.3.1 Asia CAR T-Cell Therapy Market Size by Application (2021-2026)
- 10.3.2 Asia CAR T-Cell Therapy Market Size by Application (2027-2032)
- 10.3.3 Asia CAR T-Cell Therapy Market Share by Application (2021-2032)
- 10.4 Asia CAR T-Cell Therapy Market Size by Country
- 10.4.1 Asia CAR T-Cell Therapy Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia CAR T-Cell Therapy Market Size by Country (2021-2026)
- 10.4.3 Asia CAR T-Cell Therapy Market Size by Country (2027-2032)
- 10.4.4 Asia CAR T-Cell Therapy Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa CAR T-Cell Therapy Market Size (2021-2032)
- 11.2 South America, Middle East & Africa CAR T-Cell Therapy Market Size by Type
- 11.2.1 South America, Middle East & Africa CAR T-Cell Therapy Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa CAR T-Cell Therapy Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa CAR T-Cell Therapy Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa CAR T-Cell Therapy Market Size by Application
- 11.3.1 South America, Middle East & Africa CAR T-Cell Therapy Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa CAR T-Cell Therapy Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa CAR T-Cell Therapy Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa CAR T-Cell Therapy Market Size by Country
- 11.4.1 South America, Middle East & Africa CAR T-Cell Therapy Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa CAR T-Cell Therapy Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa CAR T-Cell Therapy Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa CAR T-Cell Therapy Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst